Stanford Alzheimer's Disease Research Center

斯坦福阿尔茨海默病研究中心

• 批准号: 10647859
• 负责人: Victor Henderson
• 金额: $ 329.9万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10647859
• 关键词: Adult; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Area; Artificial Intelligence; Big Data; Bioinformatics; Biological Markers; Biometry; Blood; Brain; Brain imaging; Cell Line; Cells; Clinical; Clinical Management; Cognitive aging; Communities; Consent; Consultations; Data; Data Set; Dementia with Lewy Bodies; Development; Diagnosis; Disease; Early Diagnosis; Education; Elderly; Family; Feces; Fibroblasts; Foundations; Funding; Future; Goals; Hispanic; Human Resources; Image; Immune; Impaired cognition; Latino; Lewy Bodies; Lewy body pathology; Lewy neurites; Link; Liquid substance; Meninges; Mission; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Participant; Pathogenesis; Pathologic; Persons; Phenotype; Plasma; Population; Proteomics; Research; Research Personnel; Research Support; Research Training; Resistance; Resource Sharing; Resources; Risk; Skin; Solid; Structure; Therapeutic; Training; Training Support; alpha synuclein; brain tissue; community engagement; data management; disparity reduction; ethnic minority population; high risk; improved; innovation; insight; investigator training; microbiome; motor impairment; multidisciplinary; neuroimaging marker; neuropathology; outreach; pre-clinical; prevent; racial minority population; recruit; repository; resilience; statistics; stool sample; tool; whole genome

1. SUMMARY (Overall) The National Alzheimer's Project Act establishes an integrated national plan to overcome Alzheimer's disease (AD); develop treatments to prevent, halt, or reverse the course of AD; improve the early diagnosis of AD; and decrease disparities in AD for ethnic and racial minority populations at higher risk for AD. In this context, AD is intended to encompass AD-related dementias, including dementia with Lewy bodies. In support of the goals and research milestones of the National Alzheimer's Project Act, the mission of the Stanford Alzheimer's Disease Research Center (ADRC) is to serve as a shared resource to facilitate and enhance research on AD and the spectrum of cognitive impairment associated with Lewy body (LB) pathology. We follow a strategy of deep phenotyping, believing that critical answers emerge more readily when investigators are able to delve deeply within and across multiple levels of participant data. Healthy adults without cognitive or motor impairment serve both as a comparison (control) population and as a preclinical population in which mechanisms of cognitive aging and clinical transition can be studied. People with Parkinson's disease without cognitive impairment also serve as comparators and as an at-risk transitional population for the development of cognitive impairment linked to LB pathology. ADRC resources will provide investigators with unique opportunities for the parallel study of these two neurodegenerative disorders, enabling insights into pathogenesis, preclinical diagnosis, transitions, resistance and resilience, and therapeutic approaches. Aims of the Stanford ADRC are to (1) provide an administrative structure that advances the mission of the center; (2) develop and maintain human resources for studies of the AD spectrum and the LB spectrum of cognitive impairment, as well as cognitive aging; (3) make available well-characterized brain tissues, brain-derived biospecimens, and quantitative molecular data derived from high-content imaging of brain tissues; (4) make available participant biospecimens and high-content biospecimen data; (5) provide structural, functional, and molecular neuroimaging biomarkers in support of research on AD-spectrum cognitive impairment, LB-spectrum cognitive impairment, and cognitive aging; (6) provide for the management of Stanford ADRC data, prepare research datasets, provide high-level biostatistical consultation for ADRC investigators, and support research on big data using tools from biostatistics, bioinformatics, and artificial intelligence; (7) with our community partners, provide respectful, culturally sensitive outreach and provide opportunities for education, training, and research participation for healthy adults, people with AD-spectrum and LB-spectrum disorders, and their families. Stanford ADRC outreach and community engagement extends particularly to urban Hispanic/Latino older adults, an important Bay Area population, which is under-represented in AD-related research; and (8) support the training of investigators and future leaders in the field of AD and related dementia.

1.摘要(整体) 《国家阿尔茨海默氏症项目法》确立了克服阿尔茨海默氏症的综合国家计划 (AD)；开发预防、阻止或逆转AD病程的治疗方法；改进AD的早期诊断；以及 减少阿尔茨海默病风险较高的少数民族和少数族裔人群在阿尔茨海默病方面的差异。在这种情况下，AD是 旨在涵盖与AD相关的痴呆，包括路易体痴呆。支持实现千年发展目标 和国家阿尔茨海默氏症项目法案的研究里程碑，斯坦福阿尔茨海默氏症的使命 疾病研究中心(ADRC)将作为促进和加强AD研究的共享资源 以及与路易小体(LB)病理相关的认知障碍的频谱。我们遵循的战略是 深入的表型分析，认为当调查人员能够深入研究时，关键答案更容易出现 深入多个级别的参与者数据。没有认知或运动能力的健康成年人 损害既可以作为比较(对照)人群，也可以作为临床前人群 认知老化和临床过渡的机制可以研究。帕金森氏症患者没有 认知障碍也可作为对照和高危过渡性人群发展 认知障碍与脑白质瘤病理有关。ADRC资源将为调查人员提供独特的 这两种神经退行性疾病的平行研究机会，使人们能够深入了解 发病机制，临床前诊断，转变，抵抗和恢复，以及治疗方法。的目标 斯坦福发展研究中心(Stanford ADRC)将(1)提供一个推进中心使命的行政结构；(2) 开发和维护人力资源，以研究AD谱和认知能力的LB谱 损伤以及认知老化；(3)提供具有良好特征的脑组织，脑源性 来自脑组织高含量成像的生物样品和定量分子数据； 可用的参与者生物样品和高含量生物样品数据；(5)提供结构、功能和 支持AD谱系认知障碍研究的分子神经影像生物标志物 认知功能障碍和认知老化；(6)为管理斯坦福ADRC数据，准备 研究数据集，为ADRC调查人员提供高水平的生物统计咨询，并支持研究 使用生物统计学、生物信息学和人工智能的工具研究大数据；(7)与我们的社区 合作伙伴，提供尊重的、对文化敏感的外展，并提供教育、培训和 健康成年人、AD谱系和LB谱系障碍患者以及他们的研究参与 家人。斯坦福ADRC的外展和社区参与特别扩展到城市拉美裔/拉丁裔 老年人，湾区的一个重要人口，在AD相关研究中代表性不足；以及(8) 支持AD及相关痴呆症领域的研究人员和未来领导者的培训。